COMMUNIQUÉS West-GlobeNewswire

23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
25/08/2026
Reddick, a 13-time NASCAR Cup Series winner and 2026 Daytona 500 Champion, shares how prioritizing sleep health is an important part of his recovery and performance routine SAN DIEGO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- [...]
Standard Process Launches GI Soothing Supplement for Dogs and Cats
25/08/2026
New probiotic, postbiotic, and botanical formula provides comprehensive gastrointestinal support during periods of digestive upset or distress A Media Snippet accompanying this announcement is available by clicking on [...]
Investors and Entrepreneurs Agree: AI, Enterprise Demand and Investor Confidence Are Reshaping Pharma Tech, According to New McKesson Ventures Report
25/08/2026
Top healthcare investors and entrepreneurs weigh in on priorities, challenges and the direction of innovation across the pharmaceutical value chain SAN FRANCISCO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pharma technology is [...]
From Margaritas to Medicine: Construction Advances at Ally Medical ER Liberty Hill
25/08/2026
The more than 8,000-square-foot facility takes shape on State Highway 29 in the former home of a beloved local Tex-Mex restaurant. LIBERTY HILL, Texas, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Liberty Hill families will soon [...]
10X Health Expands its Flagship Genetic Test to Now Analyze 27 Genes, Providing the Most Comprehensive Methylation Panel Available
25/08/2026
The expanded Methylation Genetic Test from 10X Health is available at no additional cost, is paired with a wellness concierge, and provides customized protocols SCOTTSDALE, Ariz., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Today [...]
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) Funding Update
25/08/2026
HENDERSON, Nev., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) is continuing its ongoing negotiation with investors from Thailand, Japan, Switzerland, Luxembourg, USA, Bulgaria, and the UAE [...]
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
25/08/2026
Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-line GEA Second FDA [...]
Trading in GN Store Nord shares by board members, executives and associated persons
25/08/2026
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
Astrocyte Pharmaceuticals Receives NIH Award to Evaluate AST-004 in Substance Use Disorders
25/08/2026
$400,000 program extends AST-004 into another major CNS indication and reinforces the breadth of its cerebroprotective potential GROTON, Conn., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Astrocyte Pharmaceuticals Inc. , a [...]
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
25/08/2026
Beyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upon closing Beyond Air eligible to receive up to $32.5 million in development and commercial milestone payments GARDEN [...]
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
25/08/2026
CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by [...]
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
25/08/2026
BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Immatics Announces $150 Million Underwritten Offering
25/08/2026
Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell [...]
Aveanna to Participate in the 2026 Jefferies Healthcare Services and Technology Conference
25/08/2026
ATLANTA, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the 2026 Jefferies Healthcare Services and Technology [...]
Lumexa Imaging Announces Participation in Upcoming Investor Conferences
25/08/2026
RALEIGH, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging Holdings, Inc. (“Lumexa Imaging”) (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, announced today that Caitlin Zulla [...]
BrewDog Wins Big at the 2026 World Beer Awards with a Sweeping Show of Brewing Excellence
25/08/2026
Hazy Jane, Wingman and Mackie’s Two Scoops Earn Gold and Scotland Country Winner Awards, with Punk IPA, Lost Lager, Black Heart and Mello Also Recognised Among the World’s Best Beers ELLON, Scotland and LONDON, Aug. 25 [...]
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
25/08/2026
All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet [...]
Apollo Therapeutics Announces Positive Immunogenicity Data and Cross-Species Activity from Phase 1 Trial of APL-10456, a Pan-Rhinovirus Vaccine for the Prevention of COPD Exacerbations
25/08/2026
Enrollment and dosing completed in Phase 1 randomized controlled trial (n=144) evaluating the safety, tolerability, immunogenicity and cross-species activity of APL-10456, an investigational rhinovirus vaccine Initial [...]
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
25/08/2026
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to <12 years in Japan — RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, [...]

Pages